Status:
COMPLETED
Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment
Lead Sponsor:
New York State Psychiatric Institute
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
Depression
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
This study will use pre-treatment positron emission topography and functional magnetic resonance imaging scans of the brain to predict the most effective antidepressant treatment for people with major...
Detailed Description
Major depressive disorder (MDD) is characterized by a combination of symptoms that can interfere with a person's ability to work, study, sleep, eat, and enjoy activities that were once pleasurable. St...
Eligibility Criteria
Inclusion
- Diagnosis of current major depressive disorder
- Currently depressed
- Subjects must be generally healthy with no significant medical problems, anemia/blood loss, or cardiac abnormalities
- Likely to tolerate medication washout
- Capacity to provide informed consent
- Off of anti-coagulant/anti-platelet treatment for 10 days
- Willing to travel to Brookhaven for PET scanning
Exclusion
- Current abuse of or dependence on alcohol or another substance (\>6 months remission okay)
- History of other major psychiatric disorders such as bipolar, schizophrenia, schizoaffective; anorexia or bulimia in past year
- First degree family history of schizophrenia if subject is under 33
- Unable/unwilling to discontinue all psychotropic medication that affects the serotonin system
- Pregnant, breastfeeding, or planning to become pregnant during the study
- A medical contraindication to antidepressants
- Dementia
- Prior head trauma with evidence of cognitive impairment
- Well-documented failure of two or more SSRI AND tricyclic antidepressant (TCA) trials of adequate dose and duration
- Metal implants, pacemaker, metal protheses or orthodontic appliance, the presence of shrapnel
- Current past, present, or anticipated exposure to radiation
- Actively suicidal
- Lifetime history of glaucoma
- Lack of response to \>2 trials of antidepressant monotherapy of adequate dose and duration
- Claustrophobia
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2012
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT00456014
Start Date
September 1 2006
End Date
May 1 2012
Last Update
March 19 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Columbia University/New York State Psychiatric Institute
New York, New York, United States, 10032